Astellas Pharma

Astellas Pharma

Community score

+0.83 -55
Industry: Biotechnology & Pharmaceuticals
Listing country: Japan
Year added: 2018

Incorporated in 2005, Astellas Pharma is a pharmaceutical company with its headquarters in Tokyo, Japan. The company operates in a variety of business segments including Transplantation, Urology, Oncology, Neuroscience, Infectious Diseases, Immunology, Diabetes and Metabolic Diseases, Cardiovascular, and Regenerative Medicine. Astellas Pharma is recognized for key brands such as Prograf (tacrolimus), an immunosuppressant prescribed for organ transplantation; Xtandi (enzalutamide), used in treating prostate cancer; and Vesicare (solifenacin) along with Betanis/Myrbetriq/Betmiga (mirabegron), both of which address overactive bladder conditions. The company's products and services have a broad international reach, being sold in various key markets across the United States, Japan, Europe, Asia, and other global regions, either through direct sales or partnerships. (Powered by AI)

Show Company Information
You view a limited profile page without scores and metrics availability. Subscribing users get to see more advanced data, want to see it in action? Click on a company you are interested in: .
My impact scoreBeta
List View
Astellas Pharma

According to the WHO, ~785 Million (Mn) people do not have access to basic drinking water services1, while 2.7 Billion (Bn) people are experiencing water scarcity at least a month in a year2. The world's total water demand is 4,600 Bn m3 at presen...

Renu R. January 23rd, 2024
30 ratings
Astellas Pharma

Research and development (R&D) investments assist in developing drugs that save lives1. Globally, prostate cancer (PC) is the 4th common cancer and affected 1.4 million (Mn) people in 20202,3. Annually, 546 Mn people are affected by Overactive bla...

Abdulmajeed V. January 16th, 2024
22 ratings
Astellas Pharma

Around 2 billion (Bn) people worldwide lack access to essential medications1;p1. Half of the global population avoids medical care because of the out-of-pocket cost2. The median income in the US is around USD83,600 per person per year in FY20233.

...
Fabian N. January 11th, 2024
22 ratings
Astellas Pharma

In order to ensure strong institutions and the well-being of society, governments spend a considerable amount of the state's budget on public goods and services, which are funded by taxes paid by individuals and corporations1. Corporate taxes acco...

Muhammad S. November 6th, 2023
16 ratings
Astellas Pharma

Women are frequently treated differently at the workplace through wage discrimination & institutional challenges indicating inequality1. The ILO considers a gender-balanced workplace to have 40%-60% of either gender2;pxii. Gender equality may resu...

Honey S. November 30th, 2023
20 ratings
Astellas Pharma

A diverse and inclusive workplace gives a sense of belonging to minorities1. However, people are often discriminated against based on age, disability, ethnicity, race, etc2. Disabled people face various barriers to employment and are socially excl...

Renu R. September 11th, 2023
16 ratings
Astellas Pharma

In 2022, approximately 3.4 billion (Bn) individuals were employed worldwide1. Job creation is essential for society, as well as for the economy2. It fuels economic growth as the spending of wages leads to a higher consumer spending, reduces povert...

Feyisayo Favour F. August 22nd, 2023
18 ratings
Astellas Pharma

Packaging waste leakage, especially plastic waste, into the environment, has significantly increased in recent years1, wherein 40% of plastic waste ends up in landfills1. Plastics can take 20 to 500 years to decompose, depending on the material an...

Gift O. June 2nd, 2023
24 ratings
Astellas Pharma

Greenhouse gas (GHG) emissions are responsible for various adverse environmental effects, such as the rise in the average temperature of the planet & climate change1. Also, it is reported that 100,000+ climate change-related deaths happen each yea...

Rasheed S. May 20th, 2023
29 ratings
Astellas Pharma

Posterior reversible encephalopathy syndrome (PRES) is an acute neurotoxic syndrome characterized by headache, impairment of consciousness, seizures, visual disturbances, and neurological deficits3. Long PRES can lead to death9;p3

Astellas Pharm...

Claudia M. March 8th, 2022
34 ratings

Most negative / positive SDG

+2.56
-3.11